HAE Australasia are delighted and appreciative of the ground breaking decision from Pharmac in New Zealand to fund Icatibant (Firazyr) for eligible patients living with Hereditary Angioedema.
The decision will allow patients in need of an effective treatment to greatly improve their quality of life and bring their treatment options in line with those available in Australia.
Patients in New Zealand, as in Australia need to see a clinical immunologist to have Icatibant prescribed initially. Follow up prescriptions can then be prescribed by your local family physician.
A huge thank you to all of the patients and carers that sent in submissions in support of funding. Full details of the decision is available on Pharmac’s website. (link is external)Please
Shane Burke, one of our patients who contributed to the submission was interviewed by Stuff.co.nz(link is external) regarding the funding decision.